Which country is the drug Ivonib developed and produced in?

Ivosidenib (Ivosidenib) is a targeted therapy drug developed and originally produced by the American pharmaceutical company Agios Pharmaceuticals. It is specially used to treat cancers with isocitrate dehydrogenase 1 (IDH1) gene mutations, especially in hematological tumors such as relapsed/refractory Acute Myeloid Leukemia (AML) and cholangiocarcinoma. It has significant efficacy. This drug was first approved by the US FDA in 2018 and is the world's first oral small molecule inhibitor targeting IDH1 mutations.

Agios has been deeply involved in the field of metabolism for many years, focusing on targeted therapy of tumor metabolism abnormalities and mutation targets. The development of ivosidenib is based on its understanding that the 2-hydroxyglutarate (2-HG) metabolite produced after IDH1 mutation will inhibit the normal differentiation of hematopoietic cells. By selectively inhibiting the activity of the mutant IDH1 enzyme, ivosidenib can reverse the abnormal accumulation of 2-HG and promote the differentiation and apoptosis of tumor cells.

AlthoughAgios was the original R&D company of ivonib, but its commercialization rights were transferred to French pharmaceutical giant Sanofi at a later stage. This means that Sanofi is mainly responsible for the production, sales and regulatory affairs of Avonib currently on the market globally. In the U.S. market, this drug is marketed under the trade name Tibsovo, and has gradually expanded to Europe, Japan and other regions. At the same time, pre-market clinical studies or "compassionate use" programs have also been launched in many countries.

It is worth noting that due to its ability to target gene mutations, the drug has been included as a representative product in the field of precision medicine and is expected to expand its indications in more IDH1-related tumors in the future. For countries that have not yet introduced this drug, patients can obtain treatment through international drug direct mail platforms or overseas medical treatment.

Reference: https://www.tibsovo.com/